Nucleai
Nucleai is a spatial biology company that has built an AI-powered multimodal platform for analyzing tissue biopsies to discover spatial biomarkers and predict patient response to oncology therapies, primarily serving top-tier biopharmaceutical companies, life-science tools partners, and academic research institutions globally.
- Company typePrivate
- Founded2018
- HeadquartersChicago, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Nucleai does
Nucleai is a spatial biology company founded in 2017/2018 in Israel by Avi Veidman, applying geospatial and satellite-imagery AI techniques to the analysis of tissue biopsies. The company has built an AI-powered multimodal spatial biology platform that ingests H&E, IHC, multiplex immunofluorescence (mIF), and spatial transcriptomics images to perform spatial biomarker discovery, scoring, and prediction of therapy response. The platform is delivered as a cloud application (app.nucleai.cloud) and includes specialized deep-learning models — including a high-plex imaging normalization model with reported 20x speedup and an LLM-based spatial proteomics agent that generates automated reports — supported by peer-reviewed publications in Nature Communications and Modern Pathology.
Nucleai's customer base is concentrated in the top tier of biopharmaceutical companies, with stated engagement with 20+ pharma customers including Gilead, Amgen, and other Top 20 Biopharma. Revenue is generated through three primary streams: enterprise SaaS and platform licensing to biopharma, strategic co-development arrangements with CROs (Sirona Dx) and life-science tools companies (Bio-Techne/Lunaphore), and research-use-only image analysis services for academic and translational research. The company operates a dual-headquarters structure with offices in Tel Aviv, Israel (R&D and engineering) and Chicago, Illinois (US commercial operations).
Total disclosed equity funding is approximately $60M, raised across a 2022 $33M Series B led by Section 32 and Sanofi Ventures, a 2024 $14M strategic round led by M Ventures (Merck KGaA), and earlier rounds. Strategic pharma CVCs (Sanofi Ventures, M Ventures, Debiopharm) sit alongside financial investors (Section 32, Vertex Ventures, Grove Ventures), and the investor mix is directly leveraged through partnership channels into Bio-Techne, Sirona Dx, and academic translational programs such as the University of Glasgow SPARC colorectal cancer initiative. Headcount is reported in the 51-100 range.
Nucleai firmographics
Firmographics- Name
- Nucleai
- Legal name
- Nucleai Ltd.
- Website
- https://nucleai.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Nucleai is a spatial biology company that has built an AI-powered multimodal platform for analyzing tissue biopsies to discover spatial biomarkers and predict patient response to oncology therapies, primarily serving top-tier biopharmaceutical companies, life-science tools partners, and academic research institutions globally.
- Ownership category
- akta.pro rank
Nucleai industry classification
Industry- Product category
- Spatial Biology AI Software
- NAICS
- Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (51821)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industry
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where Nucleai is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Nucleai business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- Enterprise SaaS / Platform Licensing: Nucleai's "Solution" is provided as an image analysis and biomarker discovery platform delivered via a cloud application (app.nucleai.cloud) under customer agreements. The Nucleai Platform and its Results are governed by Customer Agreements that govern usage rights, indicating recurring enterprise licensing/subscription revenue from biopharma customers.
- Strategic Co-Development / Custom Project Engagements: Project-based, milestone-driven revenue from joint spatial proteomics and biomarker discovery programs with biopharma, CROs (e.g., Sirona Dx integrated end-to-end offering), and academic partners (e.g., University of Glasgow SPARC). May combine licensing with services for assay design, validation, and bespoke AI analysis.
- Research Use Only (RUO) Image Analysis Tooling: The Solution is explicitly designated "for research use only (RUO) and not intended for diagnostic purposes" per User Terms — revenue currently derived from RUO analytical workflows, with stated ambition to transition into clinical diagnostic products (companion diagnostics) over the next 2–5 years per CEO.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Quote-based enterprise agreement (no public price list) |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels9 records
Nucleai product offering
Product offeringCore offering
Nucleai provides an AI-powered multimodal spatial biomarker analysis platform delivered as a cloud-based application (app.nucleai.cloud) that ingests H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics images alongside clinical data to identify predictive spatial biomarkers, automate biomarker scoring, and predict response to therapy. The platform is licensed to biopharma, CRO, and academic customers under enterprise Customer Agreements and is paired with strategic co-development engagements, an automated deep learning model for high-plex normalization, and an AI-powered spatial proteomics agent for report generation.
Product overview
Nucleai offers a single unified AI-driven spatial biomarker analysis platform (a "multimodal spatial operating system") with an add-on deep-learning model, an AI-powered spatial proteomics agent, an Analysis Studio viewer, and an OD-based quantitative biomarker scoring solution. The core platform powers six solution areas: Biomarker Discovery & Validation, Biomarker Scoring, Genomic Biomarker Screening, Mechanism of Action (MoA), Data Enrichment, and Companion Diagnostics, with companion-diagnostic deployments also enabled through the Sirona Dx partnership. The Analysis Studio is the interactive viewer layered on top of the platform, the deep-learning model automates spatial proteomics interpretation, the AI-powered spatial proteomics agent uses LLMs to surface insights and generate reports, and the OD-based quantitative biomarker scoring module standardizes quantification within the platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Nucleai Spatial Biomarker Analysis Platform AI-driven multimodal spatial operating system that ingests high-plex imaging, histopathology, and clinical outcome data to support spatial biomarker discovery, scoring, mechanism-of-action studies, and prediction of therapy response for biopharma, academic, and CRO customers.
- Deep Learning Model for Spatial Proteomics First-of-its-kind deep learning model that automates normalization of high-plex mIF imaging data and biomarker quantification, ~20x faster than manual methods, running in minutes and scaling across hundreds of samples.
- AI-Powered Spatial Proteomics Agent LLM-powered agent that surfaces insights and auto-generates narrative reports from spatial proteomics datasets, enabling researchers to explore complex spatial data without specialized support.
- Analysis Studio Interactive viewer that lets users navigate cell types, marker expression, and spatial neighborhoods across tissue regions, enabling exploration of complex spatial datasets without specialized support.
- OD-based Quantitative Biomarker Scoring Optical density-based quantitative biomarker scoring that solves challenges of manual visual IHC scoring by pathologists, enabling high-sensitivity detection of low-level biomarker expression and subcellular (membrane vs. cytoplasm) protein expression.
Quantifiable outcome
- Prediction accuracy improved from ~30% to 70–80% by incorporating spatial biology context into patient response prediction
- +3 more outcomes
Companies that use Nucleai
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Nucleai technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability11 records
Feature6 records
Nucleai partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship cro co-delivery partnership for end-to-end spatial proteomics solution, flagship academic partnership for global precision medicine network launch, flagship life-science tools integration partner since 2022, key clinical research collaborator for secombit trial and melanoma program, key research collaboration for translational nsclc insights, data/institutional partner (clinical research site), strategic investor and data/institutional partner (dual role — also financial) and strategic pharma partner and investor (dual role — also financial via m ventures).
- Sirona Dxflagship cro co-delivery partnership for end-to-end spatial proteomics solutionStrategic partnership to deliver a fully integrated, scalable spatial proteomics solution for pharmaceutical and biotechnology companies. Sirona Dx (GCLP- and CLIA-accredited Technical CRO) leads assay design, development, and validation; Nucleai delivers AI-powered spatial analytics from feature extraction through biomarker discovery and biological interpretation. Joint offering covers oncology, immunology, and neuroscience applications including biomarker discovery/validation, patient stratification, MoA studies, and clinical trial biomarker programs.
- University of Glasgow (SPARC — Spatial Pathology Analytics for Research and Clinical Integration)flagship academic partnership for global precision medicine network launchCollaboration to identify and validate predictive biomarkers for colorectal cancer (CRC) and advanced polyp incidence, leveraging the INCISE study cohort. Combines Glasgow's SPARC spatial-omics capability with Nucleai's multimodal spatial pipeline integrating mIF, IHC, H&E, and clinical data. The project will analyze tissue architecture, cell-to-cell interactions, and molecular signaling to enable clinically validated precision diagnostic products for risk prediction and surveillance. Quote: "Deep phenotyping of pathology specimens using spatial omics technologies has the potential to revolutionize our understanding of disease mechanisms and progression." (Prof. Nigel Jamieson).
- Bio-Techne Corporation (NASDAQ: TECH) — including Lunaphore (COMET, SPYRE, ProximityScope)flagship life-science tools integration partner since 2022Co-developed high-plex mIF + AI multimodal biomarker analysis workflow. The SECOMBIT clinical trial study used Bio-Techne's COMET platform with a 28-plex mIF panel and Nucleai's multimodal spatial operating system to profile 42 pre-treatment metastatic melanoma biopsies across three ICB treatment arms. Joint SITC 2024 and 2025 presentations; co-marketed at AACR/ASCO/SITC booths.
- University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale (Prof. Paolo Ascierto)key clinical research collaborator for secombit trial and melanoma programResearch collaboration on the SECOMBIT clinical trial, integrating a 28-plex mIF IO panel with Nucleai's multimodal AI biomarker analysis to profile 42 pre-treatment biopsies from metastatic melanoma patients. Co-presented at SITC 2024/2025 and ASCO 2025 (Poster #247328).
- University of Queensland (Dr. Arutha Kulasinghe, Frazer Institute) and Yale School of Medicine (Dr. David Rimm)key research collaboration for translational nsclc insightsResearch collaboration profiling metabolic states of tumor and immune cells in NSCLC patients treated with checkpoint inhibitors. Nucleai's AI biomarker platform and scientific expertise were used to rapidly analyze spatial data from multiple patient cohorts and extract clinically relevant insights, published in Nature Communications (2026). SITC 2024 abstract #109.
- Mayo Clinicdata/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- University of Pennsylvania (UPenn)data/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- Fox Chase Cancer Centerdata/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- Thomas Jefferson University (Jefferson)data/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- Sheba Medical Center (Israel)data/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- Kaplan Medical Center (Israel)data/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- Rambam Health Care Campus (Israel)data/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- Clalit Health Services (Israel)data/institutional partner (clinical research site)Listed on Nucleai's homepage as a Data and Institutional Partner. Referenced as a clinical research site for the company's spatial biomarker work.
- Debiopharm (Innovation Fund)strategic investor and data/institutional partner (dual role — also financial)Listed on Nucleai's homepage as both a Data/Institutional Partner and Investor. Debiopharm Innovation Fund holds a board seat (Tom Gibbs) and Debiopharm has a board observer (Antoine Attinger).
- Merck KGaA / EMD (EMD Serono)strategic pharma partner and investor (dual role — also financial via m ventures)Listed on Nucleai's homepage as a Data/Institutional Partner. Connected to M Ventures (the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany) which led the $14M investment in April 2024. Noga Yerushalmi, PhD, Investment Director at M Ventures, sits on Nucleai's board.
Scale indicators11 records
Recent moves6 records
Expansion highlights8 records
Nucleai competitors and assessment
Company assessmentDirect peers
- PathAI: Boston-based AI pathology company offering a digital pathology platform and biomarker discovery services for biopharma, with a comparable product-market fit in AI-driven tissue analysis for pharma R&D and clinical trial support.
- Owkin: AI-for-drug-discovery company that applies multimodal machine learning to patient data (including pathology) for biopharma, with overlapping use cases in biomarker discovery, patient stratification, and clinical trial optimization.
- Akoya Biosciences: Spatial biology company offering multiplexed immunofluorescence and RNA-ISH platforms (PhenoCycler, PhenoImager) with its own AI-driven tissue analysis and biopharma biomarker discovery services, directly competitive in spatial biomarker workflows.
- Lunit: South Korea-based AI pathology company (Lunit SCOPE) with biopharma partnerships for biomarker analysis and predictive biomarker development in oncology, with overlapping customers and use cases to Nucleai.
- Proscia: AI-powered digital pathology platform company serving biopharma and clinical diagnostics with H&E-based AI biomarker solutions; competes for pharma R&D pathology budgets with a more pathology-software-centric offering.
- Ibex Medical Analytics: Israel-based AI pathology company with a strong H&E-based cancer detection platform that also serves biopharma; competes for clinical trial pathology workflows and shares Nucleai's Israel-based R&D ecosystem.
Broad incumbents
- 10x Genomics: Dominant spatial transcriptomics and single-cell platform company (Visium, Xenium) that is increasingly building downstream AI analytics; a broad incumbent whose customers overlap with Nucleai's biopharma and academic end markets.
- Bruker (NanoString spatial biology): Acquired NanoString's spatial biology assets in 2024, including the GeoMx and CosMx spatial platforms, and is a large incumbent competing across multiplex spatial biology workflows that overlap with Nucleai's biopharma end market.
Emerging players
- Aignostics: Berlin-based AI pathology company spun out of Charité, focused on multimodal AI-driven biomarker discovery for biopharma; competes for European pharma and academic spatial biomarker engagements.
- DoMore Diagnostics: Norway-based AI pathology company developing AI biomarkers for cancer prognosis and treatment prediction; comparable in addressing the AI-biomarker-for-therapy-response use case for biopharma partners.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Nucleai social profiles
Digital presenceNucleai compliance and trust
Trust signalCompliance2 records
Nucleai financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nucleai leadership team
Management profileNumber of profiles
Profiles15 records
Nucleai subsidiaries and ownership
Company hierarchySubsidiaries1 record
Nucleai funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nucleai M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nucleai
What does Nucleai do?
Nucleai provides an AI-powered multimodal spatial biomarker analysis platform delivered as a cloud-based application (app.nucleai.cloud) that ingests H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics images alongside clinical data to identify predictive spatial biomarkers, automate biomarker scoring, and predict response to therapy. The platform is licensed to biopharma, CRO, and academic customers under enterprise Customer Agreements and is paired with strategic co-development engagements, an automated deep learning model for high-plex normalization, and an AI-powered spatial proteomics agent for report generation.
Is Nucleai a public or private company?
Nucleai is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nucleai founded?
Nucleai was founded in 2018. It employs 51 to 100 people.
Where is Nucleai based?
Nucleai is headquartered in Chicago, United States, in the North America region.
How does Nucleai make money?
Three revenue lines are on record. Enterprise SaaS / Platform Licensing is the primary driver. The others are strategic Co-Development / Custom Project Engagements and research Use Only (RUO) Image Analysis Tooling.
Who are Nucleai's main competitors?
Direct peers on record are PathAI, Owkin, Akoya Biosciences, Lunit, Proscia and Ibex Medical Analytics. Broad incumbents are 10x Genomics and Bruker (NanoString spatial biology). Emerging players are Aignostics and DoMore Diagnostics.
Does Nucleai have an API?
No public API is recorded for Nucleai.
What industry is Nucleai in?
Nucleai's product category is Spatial Biology AI Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 51821 and its SIC code is 7372.